Annovis Bio (ANVS) said Monday it priced an underwritten public offering of about 5.3 million common shares and warrants to buy 5.3 million common shares at a combined price of $4 per share.
The company said the warrants will have an exercise price of $5 per share.
Total gross proceeds from the offering, which is expected to close on Tuesday, are expected to be $21 million, the company said.
Annovis Bio said it plans to use the net proceeds mainly for working capital and general corporate purposes, including the continued clinical development of its lead compound, Buntanetap.
The company's shares slipped past 30% in recent trading.
Price: 3.40, Change: -1.48, Percent Change: -30.29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.